Vinay Prassad

...

Martha McHardy

By Martha McHardy

US News Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A top official at the U.S. Food and Drug Administration (FDA) appointed during President Donald Trump's administration has departed less than three months into the job.

Vinay Prasad, a hematologist-oncologist, was appointed in early May to lead the FDA's Center for Biologics Evaluation and Research, putting him in charge of overseeing vaccines and other biologic medicines. He was also later named the agency's chief medical and scientific officer.

A spokesperson for Department of Health and Human Services (HHS) told Reuters in a statement: "Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family."

Read More

Trump Administration Restricting Kratom: What to Know3 min read

Trump Administration Restricting Kratom: What to Know

FDA Issues Most Serious Risk Level for Cookie Recall4 min read

FDA Issues Most Serious Risk Level for Cookie Recall

Is the FDA Doing Enough About Food Additives?7 min read

Is the FDA Doing Enough About Food Additives?

Newsweek contacted Prasad for comment via his website outside of regular working hours.

Vinay Prassad

...

Why It Matters

Prasad's departure marks another high-profile resignation from Trump's administration.

It also underscores growing political tensions and internal disagreements over how the FDA handles emerging therapies and pandemic-era policies.

What To Know

Prasad was criticized last week by right-wing activist Laura Loomer, who posted on X: "Meet Vinay Prasad: The progressive leftist saboteur undermining President Trump's FDA."

Loomer highlighted Prasad's previous podcast appearances and social media posts, saying he expressed "disdain" for Trump.

Former Republican Senator Rick Santorum echoed the criticism, calling Prasad "the man destroying President Donald Trump's legacy for helping patients."

But FDA Commissioner Marty Makary defended Prasad last week, telling Politico that he is an "impeccable scientist... one of the greatest scientific minds of our generation."

Prasad joined the FDA after years of public criticism of some of its regulatory practices, particularly around accelerated drug approvals. He was outspoken about the agency's decision in 2023 to approve Sarepta Therapeutics' gene therapy drug, Elevidys, for Duchenne muscular dystrophy, arguing there was little evidence that it slowed or reversed the disease.

Earlier this month, the FDA asked Sarepta to halt shipments of Elevidys following a reported death of a patient in Brazil. But the agency later reversed the decision, allowing limited distribution of the drug.

Prasad also drew criticism earlier this year after he overrode FDA experts regarding the use of two Covid vaccines, according to an internal memo seen by The New York Times.

While scientists advised broad use of the two new vaccines, Prasad limited the recommendation to older adults and immunocompromised individuals, excluding younger, healthy Americans, according to the memos.

Dr Daniel Griffin, an infectious disease expert at Columbia University, told The New York Times: "It is a dark time in the history of public health when political appointees overrule expert recommendations."

What Happens Next

It has not yet been confirmed who will replace Prasad to lead the FDA's Center for Biologics Evaluation and Research.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines